Glaukos Corp Price, Chart & Factor Exposure
Free Data & Analytics AccessLatest earnings: October 28, 2026 results vs estimates
Glaukos Corp Forecast
Glaukos Corp short-term momentum is strongly positive (up over 4 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is strongly positive (8 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 123.9% a year, a typical one-standard-deviation range is 200.16–284.80 over a week, 155.75–329.21 over a month and -57.97–542.93 over a year. (Signals as of 1 Nov 2026.)
Glaukos Corp Price Chart
Glaukos Corp Factors
YoY +76.6%
YoY +178.4%
YoY +79.1%
YoY −150.3%
YoY −25.3%
YoY +159.5%
YoY +38.6%
YoY −12.0%
YoY −8.4%
YoY +117.2%
YoY +4.9%
YoY 0.0%
YoY +130.2%
Glaukos Corp fundamentals: income statement, balance sheet & cash flow
Glaukos Corp reported revenue of $507.4m and net income of -$187.7m in FY2025, the year ended 31 December 2025 — revenue up 32.3% and net income down 28.2% on the prior year. Free cash flow was -$54.0m. These figures are as reported in the filings, not restated: 14 fiscal years and 55 quarters of history, back to December 2012. 173 FINRA short-interest settlements are published alongside them, back to June 2019.
| USD millions | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
| Revenue | 507.4 | 383.5 | 314.7 | 282.9 | 294.0 |
| Cost of revenue | 114.2 | 94.0 | 75.6 | 69.0 | 66.6 |
| Gross profit | 393.2 | 289.5 | 239.1 | 213.9 | 227.4 |
| Research & development | 150.6 | 136.4 | 138.8 | 123.3 | 101.0 |
| Selling, general & admin. | 331.7 | — | — | — | — |
| Operating income | -86.7 | -122.4 | -128.7 | -82.3 | -32.9 |
| EBITDA | -146.1 | -95.6 | -82.1 | -48.8 | -1.5 |
| Interest expense | 4.6 | 10.0 | 13.6 | 13.7 | 13.4 |
| Pre-tax income | -193.0 | -145.6 | -133.7 | -98.4 | -49.3 |
| Income tax | -5.4 | 0.8 | 0.9 | 0.8 | 0.3 |
| Net income | -187.7 | -146.4 | -134.7 | -99.2 | -49.6 |
Download Glaukos Corp fundamentals
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.GKOS.NYSE&statement=all&freq=a&format=csv&years=10
Figures in USD, statements as filed and FINRA consolidated short interest. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic. Short interest is the consolidated FINRA figure for the settlement date shown, published seven to eight business days later.
Research on Glaukos Corp
Explore MacroFinance macro & markets research and analysis.
Glaukos Corp Trading Strategies
58 backtested tactical asset allocation strategies hold SPY (US market) or XLV (Health Care sector), the closest tradable exposure to Glaukos Corp; 28 of them are invested now. Strategies currently invested are listed first.
| Strategy | Style | Rebalance | Now in SPY, XLV | CAGR | Sharpe | Max DD |
|---|---|---|---|---|---|---|
| Tactical Permanent Portfolio | Conservative | Monthly | Premium · upgrade to view | |||
| Zakamulin and Giner's Optimal Trend Following | Moderate | Monthly | Premium · upgrade to view | |||
| Movement Capital's Composite Strategy | Moderate | Monthly | Premium · upgrade to view | |||
| Harry Browne's Permanent Portfolio | Conservative | Monthly | 25% | 7.0% | 0.96 | -17.2% |
| Keller and Van Putten's Flexible Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Ned Davis' Three Way Model | Moderate | Monthly | Premium · upgrade to view | |||
| 60_40 Benchmark | Moderate | Monthly | 60% | 8.2% | 0.93 | -29.5% |
| Dick Stoken's Active Combined Asset (ACA) - Monthly Trading | Moderate | Monthly | Premium · upgrade to view | |||
| PortfolioCharts' Golden Butterfly | Moderate | Monthly | 20% | 7.4% | 0.91 | -18.0% |
| US Cross-Asset Momentum | Moderate | Monthly | Premium · upgrade to view | |||
Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.
From creators
- P4 Demo Momentum by admin
- strategyx by admin
Statistical Distribution of Returns
PlusHow Glaukos Corp’s returns are distributed — and how they change in a given market regime.
Regime filters
| Market/Macro | Indicator | Criteria | Value | And (for Between) | Action |
|---|
No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.
| Statistic | All periods | Matching |
|---|
About Glaukos Corp (United States)
Glaukos Corp is a listed security in the United States. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).
Last updated: November 22, 2026
Frequently asked questions
What is Glaukos Corp?
What is the latest Glaukos Corp price?
Is Glaukos Corp in an uptrend?
How volatile is Glaukos Corp?
What factors affect Glaukos Corp?
Which trading strategies trade Glaukos Corp?
How are Glaukos Corp returns analysed?
Where can I download free Glaukos Corp historical data?
Free Glaukos Corp historical data (last 10 years)
Browse or instantly download the last 10 years of Glaukos Corp daily price history. A free account unlocks the full history, an Excel export with factors, and API access.
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.GKOS.NYSE&format=csv&years=10
| Date | Close |
|---|---|
| 2026-11-20 | 237.31 |
| 2026-11-19 | 238.1 |
| 2026-11-18 | 233.08 |
| 2026-11-17 | 243.25 |
| 2026-11-16 | 244.88 |
| 2026-11-13 | 245.72 |
| 2026-11-12 | 246.03 |
| 2026-11-11 | 247.16 |
| 2026-11-10 | 236.19 |
| 2026-11-09 | 238.74 |
About this stock
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
See how this market's returns behaved when a factor was in a given state, for example when Momentum was strong or bond yields were above 4%, and compare that with all periods.
Reading the chart
- Each bar is a return bucket; its height is the share of periods that landed there.
- All periods: every return in the date range.
- Matching periods: only the periods where all your filters were true. If orange shifts right of the grey, returns were better in that regime.
- Each period's return is the return over the following day, week or month (set by Timeframe), measured from the day the factor was read, so there is no look-ahead.
Adding a filter
- Factor: grouped the same way as the Factors section on this page (Quantitative, Country, Sector, …). Locked factors are listed but greyed out.
- Criteria: greater (>), greater or equal (≥), equal (=), smaller or equal (≤), smaller (<) or between two values.
- Value: depends on the factor.
- Momentum and Trend are signals from −1 to +1, picked as −100 to +100 in steps of 25.
- Mean Reversion is a z-score of price against its 250-day mean, picked in σ from −3 to +3.
- Everything else is a number you type. The line under the box shows the latest reading and its typical range over the last 10 years.
Add several filters to combine conditions; a period must pass every one. Narrow the window with the From/To dates or the 1Y / 5Y / 10Y / MAX buttons; Clear resets filters and dates.
Return statistics
- Unfiltered vs Filtered: all periods vs matching periods.
- Average return, Std dev and Sharpe are annualised (252 days, 52 weeks, 12 months, 6 two-month periods, 4 quarters).
- Maximum drawdown compounds non-overlapping periods; in the Filtered column it assumes you held only while the condition was true.
- Min, 25th percentile, median, 75th percentile and max are per period, not annualised.